Forth, the response rate of conventional targeted therapy is modest in target-positive patients, with 47% in HER-2 mutated gastric cancer [285], 71.2% for gefitinib in EGFR-mutated NSCLC [133], 71% for osimertinib for EGFR T790M mutated NSCLC [141], etc. Here, ERBB2 is linked to non-small cell lung carcinoma.